KALV vs VRTX · rev $13.7M vs P/E 30, rev $3.33B
Kalvista Pharmaceuticals Inc (KALV) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Kalvista Pharmaceuticals Inc (KALV) is a biotechnology company listed on NASDAQ.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US. It is led by Reshma Kewalramani FASN, M.D..
Latest reported KALV revenue for 2025-09-30 was $13.7M. Net income was -$158.9M. KALV currently screens at market cap $1.44B.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
KALV currently screens at market cap $1.44B. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the KALV and VRTX stock pages for the full models.
Not investment advice.